These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800 [TBL] [Abstract][Full Text] [Related]
3. Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review. Antonelli A; Palumbo C; Veccia A; Grisanti S; Triggiani L; Zamboni S; Furlan M; Simeone C; Magrini S; Berruti A Minerva Urol Nefrol; 2018 Aug; 70(4):370-379. PubMed ID: 29392925 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer: does sequencing matter? Weller MA; Kupelian PA; Reddy CA; Stephans KL; Tendulkar RD Clin Genitourin Cancer; 2015 Jun; 13(3):e183-9. PubMed ID: 25660127 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Approaches Prior To Radical Prostatectomy. Ryan ST; Patel DN; Parsons JK; McKay RR Cancer J; 2020; 26(1):2-12. PubMed ID: 31977379 [TBL] [Abstract][Full Text] [Related]
6. Current and emerging therapies for localized high-risk prostate cancer. Moris L; Devos G; Van den Broeck T; Milonas D; Albersen M; Berghen C; De Meerleer G; Devlies W; Everaerts W; Gevaert T; Van Poppel H; Claessens F; Joniau S Expert Rev Anticancer Ther; 2021 Mar; 21(3):267-282. PubMed ID: 33225759 [No Abstract] [Full Text] [Related]
7. Adjuvant and neoadjuvant therapies in high risk localized prostate cancer. Giannakopoulos X; Stagikas D; Charalabopoulos A; Sofikitis N; Charalabopoulos K J Exp Clin Cancer Res; 2006 Dec; 25(4):469-73. PubMed ID: 17310835 [TBL] [Abstract][Full Text] [Related]
8. Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence? Morgan SC; Dearnaley DP Expert Rev Anticancer Ther; 2009 Jul; 9(7):939-51. PubMed ID: 19589033 [TBL] [Abstract][Full Text] [Related]
9. The addition of chemotherapy in the definitive management of high risk prostate cancer. Ferris MJ; Liu Y; Ao J; Zhong J; Abugideiri M; Gillespie TW; Carthon BC; Bilen MA; Kucuk O; Jani AB Urol Oncol; 2018 Nov; 36(11):475-487. PubMed ID: 30309766 [TBL] [Abstract][Full Text] [Related]
10. Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer. Cha EK; Eastham JA Urol Oncol; 2015 May; 33(5):217-25. PubMed ID: 25596644 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer. Lam ET; Glodé LM Hematol Oncol Clin North Am; 2013 Dec; 27(6):1189-204, viii. PubMed ID: 24188258 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis. Liu W; Yao Y; Liu X; Liu Y; Zhang GM Asian J Androl; 2021; 23(4):429-436. PubMed ID: 33586699 [TBL] [Abstract][Full Text] [Related]
15. [Adjuvant and neoadjuvant drug therapy for prostate cancer]. Miller K; Lein M; Schostak M; Schrader M Urologe A; 2008 Nov; 47(11):1460-4. PubMed ID: 18813902 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials. Sonpavde G; Palapattu GS Expert Rev Anticancer Ther; 2010 Mar; 10(3):439-50. PubMed ID: 20214524 [TBL] [Abstract][Full Text] [Related]
17. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258 [TBL] [Abstract][Full Text] [Related]